Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy

Cancer Investigation

Volumn 18, Issue 1, 2000, Pages 20-27

  Katzir, Itzhak ^a   Shani, Jashovam ^a   Wolf, Walter ^b   Chatterjee Parti, Shruty ^b   Berman, Elisha ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUORINE; FLUOROURACIL; METHOTREXATE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TRIMETREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TARGETING; DRUG TRANSPORT; MALE; NONHUMAN; NOVIKOFF HEPATOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT; SOLID TUMOR; WALKER CARCINOMA;

EID: 0033971726     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009023058     Document Type: Article

References (27)

1. Henderson IC, Hayes DF, Come S, et al: New agents and medical treatments for advanced breast cancer. Semin Oncol 14:34-64, 1987.
2. Moertel CG, Holland JF, Frei E (eds): Cancer Medicine, Philadelphia, Lea & Febiger, 1982, pp 1753-1863.
3. Peters GJ, van Groeningen CJ: Clinical relevance of biochemical modulation of 5-FU. Anti-Cancer Drugs 2:233-245, 1991.
4. 19F-NMR spectroscopy. Cancer Res 51:5808-5812, 1991.
5. 19F-NMR spectroscopy pharmacokinetics. J Clin Oncol 8:1868-1873, 1990.
6. 19F-NMR. Br J Cancer 50:113-117, 1984.
7. 19F-NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 87:492-496, 1990.
8. Pinedo HH, Peters GF: 5-FU biochemistry and metabolism. J Clin Oncol 6:1653-1660, 1988.
9. 19F-MRS study in vivo. Br J Cancer 65:369-375, 1992.
10. Presant CA, Wolf W, Waluch W, et al: Association of intratumoral pharmacokinetics of 5-FU with clinical response. Lancet 43:1184-1187, 1994.
11. Damon LE, Cadman E, Benz C: Enhancement of 5-FU anti-tumor effects by the prior administration of MTX. Pharmacol Ther 43: 155-185, 1989.
12. Ajani JA, Kanojia MD, Bedikian AY: High dose MTX and 5-FU in patients with advanced colorectal carcinoma. Am J Clin Oncol 12:335-338, 1989.
13. Cadman L, Heimer R, Benz C: The influence of MTX pre-treatment on 5-FU metabolism in L1210 cells. J Biol Chem 256:1695-1699, 1981.
14. 19F-NMR in vivo. Proc. Int'l. Soc. Magn. Reson. Med. (ISMRM), April 12-18, 1997, Vancouver, BC, Canada, p. 1081 (abstract).
15. 19F-NMRS. Cancer Res 54:4321-4326, 1994.
16. 19F-MRS. J Cancer Res Clin Oncol 116:556, 1990 (abstract).
17. 19F-NMR spectroscopy for patients receiving chemotherapy with or without MTX pretreatment. Cancer Res 48:1680-1688, 1988.
18. Morse PA, Potter R: Pyrimidine metabolism in tissue culture cells derived from rat hepatoma: suspension of cultures derived from Novikoff hepatoma. Cancer Res 25:499-508, 1965.
19. 19F-NMRS. Magn Reson Med 19:113-123, 1991.
20. Lacerda JF, Goker E, Kheradpoor A, et al: Selective treatment of SCID mice bearing methotrexate-transport resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 85:2675-2679, 1995.
21. Marshall JL, Delap RL: Clinical pharmacokinetics and pharmacology of trimetrexate. Clin Pharmacokinet 26:190-200, 1994.
22. Brechner RR, D'Argenio DZ, Dahalan R, et al: Non-invasive estimation of bound and mobile platinum compounds in the kidney with a radiopharmacokinetic model. J Pharm Sci 75:873-877, 1986.
23. 19F-NMR spectroscopy. J Cancer Res Clin Oncol 117:295-304, 1991.
24. Solos GA, Grogen GA, Allegra CJ: Preclinical and clinical aspects of biomodulation of 5-FU. Cancer Treat Rev 20:11-49, 1994.
25. 19F-NMR. Br J Cancer 50:113-119, 1984.
26. 19F-NMR spectroscopic studies of metabolism of 5-FU in the liver of patients undergoing chemotherapy. Magn Reson Imaging 5:165-169, 1987.
27. Wolf W: Imaging can be much more than pretty pictures. Pharm Res 12:1821-1822, 1995.